Latest Heart failure Stories

FRAMINGHAM, Mass. and SYDNEY, Australia, Jan. 3, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 31(st) Annual J.P. Morgan Healthcare Conference at 10:30 a.m. Pacific Standard Time (1:30 p.m. EST) on Monday, January 7. The conference is...

LONDON, Jan. 3, 2013 /PRNewswire/ -- Heart Metabolics Limited announced today that it has closed the first tranche of its Series A financing with secured commitments of US$4 million. The proceeds of the Series A round will be used to advance U.S. clinical development of the company's lead drug candidate, perhexiline, for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy ("HCM"). Investors in the Series A financing include the Trans Tasman...

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study titled "Calcium Up-Regulation by Percutaneous Administration of...

FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 23(rd )Annual Healthcare Conference at 10:00 a.m. EST on Thursday, December 13, 2012. The conference is being held December 12-13 at the...

Pharmacological stress echo identifies donor hearts that would historically have been rejected Hearts previously rejected due to donors' age or other risk factors can now be declared viable for transplantation using pharmacological stress echo, according to research presented at EUROECHO and other Imaging Modalities 2012. The study1 was presented by Dr Tonino Bombardini from Pisa, Italy. EUROECHO and other Imaging Modalities 2012 is the annual meeting of the European Association of...

Brett Smith for redOrbit.com - Your Universe Online Snoring can be more than just an annoyance—if untreated it can have the same effect on the cardiovascular system as diabetes, according to new research from a Romanian medical doctor. The research, which was presented this week at the at EUROECHO and other Imaging Modalities 2012 conference by Dr. Raluca Mincu, showed that the nighttime breathing disorder is a sign of obstructive sleep apnea (OSA), a condition known to cause a...

SUNNYVALE, Calif., Dec. 5, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Jason Levin has joined the company as Chief Business Officer. Mr. Levin brings more than 18 years of industry experience to Sorbent. In this newly created role, he will oversee Sorbent's business development efforts and contribute to corporate strategy. Mr. Levin will report directly to Detlef...

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF -- a type of heart failure that until now has been impossible to treat. The study, which is published in the scientific journal JAMA, shows that the mortality rate in a group of HFPEF patients who used these medications decreased. Heart failure affects 3 per...

Digoxin, a drug that has been used worldwide for centuries to treat heart disease, is associated with a significant increase in deaths in patients with atrial fibrillation (AF), according to results from a study published online today (Wednesday) in the European Heart Journal. Digoxin is extracted from the foxglove plant (digitalis) and it helps the heart beat more strongly and with a more regular rhythm. It is commonly used in AF patients, and also in patients with heart failure. However,...

A large study addressing the effectiveness and safety of aldosterone antagonist therapy for older heart failure patients has found notable differences between the drug's results in clinical trial vs. what occurs in actual practice, according to researchers at Duke Medicine. Those differences have been noted anecdotally by doctors, and likely contributed to the slow adoption of aldosterone antagonists in clinical practice, but they had not been confirmed in a large study examining the drugs...